摘要
目的：探讨冻干人胎盘因子(PF)对肿瘤化学治疗(化疗)病人外周血象的影响。方法：共收治69例,采用自身交叉随机对照研究,即均接受2个疗程相同方案的化疗,其中一个疗程为化疗+PF (化疗+PF组),另一个疗程单用化疗(单用化疗组)。化疗+PF组d1开始用PF,隔日1次,每次18mg,im,持续3～4wk。结果：化疗后白细胞(WBC)最低点：化疗+PF组为(3．0±s 1．1)×10~9·L^(-1),单用化疗组为(2．6±1．2)×10~9·L^(-1)(P＜0．01)；WBC恢复时间：化疗+PF组和单用化疗组分别为(5±4)d和(11±20)d(P=0．005)。未发现不良反应。结论：PF可改善化疗所引起的骨髓抑制,有助提高化疗的耐受性。
AIM： To evaluate the impact of lyophilized human placenta factor （PF） on the peripheral hemogram of patients treated with chemotherapy. METHODS： Sixty-nine patients were eligible for a self-cross,randomized, and controlled study. All patients received 2 cycles of chemotherapy, including one cycle of chemotherapy plus PF （therapy group）, and another cycle of chemotherapy alone （control group） . PF was administered intramuscularly at a dose of 18 mg per person every other day from the beginning of chemotherapy for three to four weeks. RESULTS： The nadirs of WBC were （3.0±s 1.1）×10^9·L^-1 in therapy group and （2.6±1.2）×10^9·L^-1 in control group, respectively （P 〈 0.01） . The median recovery times of WBC in therapy group and control group were （5 ±4） d and （11±20） d, respectively （P = 0.005） . No adverse effect of PF was occured. CONCLUSION： PF can reduce the severity of myelosuppression induced by chemotherapy and improve the tolerance of chemotherapy.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2006年第8期598-600,共3页
Chinese Journal of New Drugs and Clinical Remedies
关键词
肿瘤
药物疗法
白细胞
多中心研究
随机对照试验
药物不良反应
胎盘因子
neoplasms
drug therapy
leukocytes
muhicenter studies
randomized controlled trials
adverse drug reactions
placenta factor
